Omeros
OMER11.1701.50% ( -0.170 )
Omeros (OMER)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indi...
- Open
- 11.100
- High
- 11.265
- Low
- 10.580
- Prev. Close
- 11.340
- Volume
- 1.72M
- Turnover
- 18.88M
- Avg Price
- 10.997
- Bid/Ask Ratio
- --
- Amplitude
- 6.04%
- 52wk High
- 17.650
- Volume Ratio
- 1.07
- Turnover Ratio
- 2.46%
Omeros Analyst Rating
View MoreForecast & Rating
Jul 27, 2026Price forecast
$33.00195.43%
Forecast & RatingBuy
3analysts
- Strong buy33.33%
- Buy0.00%
- Hold66.67%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · 10 hours ago
Fed Officials Leave Door Open to Adjustments, Driving Rebalancing Across Fragmented Equities
- rttnews · 16 hours ago
Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired
- PUBT · Jul 20 at 04:05 PM
Omeros repurchases USD 14.5 million of 9.5% convertible notes due 2029 for USD 29 million
- prnewswire · Jul 16 at 09:31 AM
10:31 ETComplement 3 Glomerulopathy Market Set for Transformation: 4 Emerging Therapies Leading the Next Growth Phase | DelveInsight
- prnewswire · Jul 9 at 07:05 PM
19:57 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
- MorningStar · Jul 6 at 07:12 PM
OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm
